The Pf Survey: what is most important to pharma employees?

Wednesday, July 28th, 2010

Work factors pic

The Pf Company Perception, Motivation and Satisfaction Survey provides a benchmark of pharmaceutical sales force opinion in areas including remuneration, satisfaction with current employer, ETMS usage and perception of other pharmaceutical companies.

As part of the research, respondents from the pharma sales force are asked to rank 18 work factors in terms of how important they feel they are and how satisfied they are with these areas at their current company.

 
There is some consistency in the responses over the last two years, demonstrating that pharmaceutical sales employees’ priorities have not really changed since 2008. The most notable variation in terms of motivation is that the respondents of 2009 place greater significance on company culture than belief in products, making the top five priorities when seeking an employer: salary, relationship with direct manager, work-life balance, job security and company culture.

 

 clip_image002

After the honest admission that salary matters most, respondents have placed value on more quality of life and relationship factors, signifying that these ‘softer’ company benefits remain very important to employees. It is unsurprising that job security is still a top priority for the work force. Although there is now more security throughout the  healthcare sales industry, most respondents will have experienced redundancy, either themselves or through the eyes of a colleague, and have not forgotten the impact this can have.

Satisfaction data for 2009 reveal that respondents are still most happy with the products that they are currently promoting, but their concern over the future pipeline is evident, revealing an awareness of the industry’s current pipeline worries due to patent expiries and low numbers of potential new blockbusters.

Car policy is also a downside for many, although salary is still mid-way up the table, demonstrating that this is not an area of particularly low satisfaction. It reflects badly on companies that two of the top five work factors in terms of motivation feature very low down for satisfaction: work-life balance and job security, indicating that employers are not doing enough to improve working hours and reduce insecurity amongst their employees.

 

The Pf Company Perception, Motivation and Satisfaction Survey has been conducted annually by HSP, publishers of Pf, since 2002. It provides a benchmark of pharma sales force remuneration, motivation, satisfaction, perception and recruitment. The survey is managed by Dr B Payne of Conker Statistics (A fellow of the Royal Statistical Society) and respondents are anonymous. These latest results were gathered in early 2010, but relate to 2009.

US GSK rep bonuses to be decided by customers

Tuesday, July 27th, 2010

Customer feedback will play a central role in deciding the bonuses that sales representatives working at GSK’s US subsidiary will receive, as part of a new scheme to be implemented from 2011 onwards.

The company is implementing a compensation system that will rely on the customer service provided by the sales professional, as well as adherence to the company’s values of transparency, integrity, respect and patient-focus.

It is part of a wider effort on the part of GSK to better target its sales staff based on the changing needs of healthcare professionals (HCPs).

“The US healthcare marketplace is changing significantly in response to demand by patients, healthcare providers and payers for higher quality care, lower costs and better health outcomes,” said Deirdre Connelly, President of North America Pharmaceuticals at GSK.

“Physicians have been telling us they want to see fewer sales professionals, and those they do see need to provide greater value in helping improve patient health. In response, we are changing the way we sell our medicines and vaccines in order to deliver the value our customers demand, in a transparent way, with integrity and respect for the patient,” she added.

GSK is hoping to align its sales efforts with the needs of US HCPs working in large health systems or integrated delivery networks where decisions on purchasing are made from a central office.

“We’ve spent a good deal of time listening to our customers, and they are asking us for more information about reimbursement, disease education and support for improving patient health,” Deirdre Connelly concluded.

Study finds EU companies are leaders in CSR

Wednesday, June 23rd, 2010

European pharma companies are still leading the way in making medicines available to people in developing countries, the second Access to Medicine Index has shown.

Compared to 2008, when the first Index was published, pharma companies have given more insight into their policies to increase access to medicines, say the researchers. They identify more industry initiatives than two years ago, but also see room for improvement.

“The Access to Medicine Index independently assesses how individual pharmaceutical companies perform in promoting universal access to essential medicines, and is thus an important tool in improving performance,” said Dr Carissa Etienne, Assistant Director-General at WHO.

“The 2010 ranking reveals important progress, if only because companies have shown far greater willingness to open up. The Index unveils great improvements, especially in the areas of research and development and equitable pricing. At the same time, it shows that the industry as a whole still has a long way to go,” added Wim Leereveld, the Index’s founder.

The Access to Medicine Index ranks 20 of the world’s largest pharmaceutical companies on their efforts to make sure that medicines are made for, and reach, people in developing countries. The Index encourages drug companies to compete and offers investors and others a way to compare their social responsibility records.

The Access to Medicine Index 2010 identifies GlaxoSmithKline (UK) as current industry leader in improving access to medicines, followed by Merck & Co. (US), Novartis (Switzerland), Gilead Sciences (US) and sanofi-aventis (France).

The Access to Medicine Index was created by the Access to Medicine Foundation and was researched by RiskMetrics ESG Analytics, part of MSCI Inc., a global provider of investment decision support tools.

 

clip_image001

US doctors welcome pharma gifts

Wednesday, June 23rd, 2010

Many US clinicians continue to hold positive attitudes toward interactions with pharmaceutical and device companies, despite recent policy changes, new research has revealed.

A report in the June issue of Archives of Surgery, one of the JAMA/Archives journals, shows that this positive attitude remains despite increased scrutiny of the relationships between clinicians and the industry.

“We now know that nearly all physicians maintain some relationship with industry, beginning with near-universal exposure to pharmaceutical industry marketing during medical school,” the authors write. “These relationships range from drug samples and free food in the workplace to larger payments, such as reimbursement for educational meetings and conferences and speaking and consulting fees.”

The research was conducted in 11 hospitals in 2008 by Deborah Korenstein, MD and her colleagues from the Mount Sinai School of Medicine consortium in New York, which has a rule banning or limiting marketing-related interactions between physicians and industry.

Of the 590 clinicians and medical students that completed the survey, 72.2% found sponsored lunches appropriate, while 74.6% found large gifts unacceptable but believed that other physicians were more likely to be influenced by gifts and food from industry than they were.

Surgeons and trainees tended to have more positive attitudes towards industry and were more likely to deem some gifts – including funding of residencies and travel expenses for attending lectures – acceptable.

Innovation leader joins ABPI

Monday, June 14th, 2010

Carol Blount has joined the ABPI as Head of Commercial Affairs, bringing more than 15 years’ senior level leadership experience within the UK pharma industry.

Her experience includes leadership of strategic innovation and change, business development and brand marketing leading to increased sales and contribution.

In her new role she will be responsible for managing all commercial affairs and initiatives within the ABPI, including NHS Joint Working and quality, innovation, prevention and productivity (QIPP) initiatives, delivery of commercial aspects of the PPRS, supply chain and distribution initiatives.

Carol initially worked for Bayer and more recently for AstraZeneca, where she developed her marketing experience, eventually becoming Head of Innovation. Carol has also successfully led a number of initiatives, including joint working projects with industry and PCTs.

“With a new Government and an uncertain financial situation throughout the world, these are challenging times for our industry,” said Carol. “I am very much looking forward to working in my new role to help tackle some of the vitally important issues facing the industry.”

Alison Clough, ABPI Commercial and Communications Director, added: “I am delighted that Carol is joining our strengthened commercial team. Her extensive experience will bring added value to our activities working with the NHS on QIPP, as well as supply shortages and other commercial issues.”